Osteogenesis imperfecta, also known as brittle bone disease, is a genetic disorder that causes weak bones formation. People with osteogenesis imperfecta generally have weak bones that break easily. Osteogenesis imperfecta is classified into eight categories, designated type I to type VIII. Osteogenesis imperfecta type I is the mildest form of the disease that is characterized by the bone fracture during adolescent and childhood stage. People with milder form of osteogenesis imperfecta are susceptible to hearing loss in adulthood. Other form of osteogenesis imperfecta are more severe in which frequent bone fracture occurs. Dentinogenesis imperfecta, respiratory problems, hearing loss, short stature, and blue sclerae are the common problems observed in osteogenesis imperfecta. Sanofi SA is in the process of developing fresolimumab as a transforming growth factor beta inhibitor for the treatment of osteogenesis imperfecta. Mereo BioPharma Group plc is in the process of developing BPS804 as a SOST protein inhibitor for the treatment of osteogenesis imperfecta. Some of the companies and universities having the pipeline of osteogenesis imperfecta include Mereo BioPharma Group plc, Amgen, Inc., Baylor College of Medicine and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.